Le 16 decembre/December 2020

	The common shares of Tryp Therapeutics Inc. have been approved for listing on the CSE.

	Listing and disclosure documents will be available at&nbsp;www.thecse.com&nbsp;on the trading date.

	The Company is a pharmaceutical company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The Company intends to do this through the development of compounds with known activity and/or safety profiles. The Company’s lead program is designed to address neurological disorders through the therapeutic dosing of synthetic psilocybin. The Company is currently evaluating potential lead indications for its psilocybin-for-neurology program, which it refers to as its PFN™ program, including fibromyalgia and Prader-Willi Syndrome. In addition to its PFN™ program, the Company is developing razoxane for the treatment of soft-tissue sarcomas. The Company continues to evaluate potential additional indications for its existing programs, as well as other drug candidates with known activity and/or safety profiles that may have utility in the treatment of rare diseases or other diseases with high unmet medical needs.

	____________________________

	 
	Les actions&nbsp;ordinaires&nbsp;de&nbsp;Tryp&nbsp;Therapeutics Inc. ont&nbsp;été&nbsp;approuvées&nbsp;pour inscription au CSE.&nbsp;

	Les documents&nbsp;d'inscription&nbsp;et de divulgation&nbsp;seront&nbsp;disponibles&nbsp;sur www.thecse.com à la date de&nbsp;négociation.&nbsp;

	La Société est une société pharmaceutique dont l'objectif est d'apporter une médecine transformatrice avec des profils de sécurité connus aux maladies sans traitement de première intention efficace. La Société a l'intention de le faire à travers le développement de composés avec des profils d'activité et / ou de sécurité connus. Le programme principal de la société est conçu pour lutter contre les troubles neurologiques grâce au dosage thérapeutique de la psilocybine synthétique. La Société évalue actuellement des indications potentielles de plomb pour son programme de psilocybine pour la neurologie, qu'elle appelle son programme PFN ™, y compris la fibromyalgie et le syndrome de Prader-Willi. En plus de son programme PFN ™, la Société développe du razoxane pour le traitement des sarcomes des tissus mous. La Société continue d'évaluer les indications supplémentaires potentielles pour ses programmes existants, ainsi que d'autres médicaments candidats avec des profils d'activité et / ou d'innocuité connus qui peuvent avoir une utilité dans le traitement de maladies rares ou d'autres maladies avec des besoins médicaux non satisfaits élevés.
<table border="1" cellpadding="1" cellspacing="1" >
<tbody>
<tr>
<td >
				Issuer/Issuer:</td>
<td _msthash="6537128" _msttexthash="342069" >
				Tryp&nbsp;Therapeutics Inc.</td>
</tr>
<tr>
<td >
				Security Type/Title:</td>
<td _msthash="6538454" _msttexthash="624468" >
				Common&nbsp;Shares/Actions&nbsp;ordinaires</td>
</tr>
<tr>
<td >
				Symbols:</td>
<td _msthash="6539780" _msttexthash="34580" >
				TRYP</td>
</tr>
<tr>
<td >
				Number of securities issued and outstanding:</td>
<td _msthash="6541106" _msttexthash="53794" >
				39 291 722</td>
</tr>
<tr>
<td >
				Number of Securities reserved for issuance:</td>
<td _msthash="6542432" _msttexthash="46423" >
				6 869 684</td>
</tr>
<tr>
<td >
				CSE Sector/Category:</td>
<td _msthash="6543758" _msttexthash="888979" >
				Life Sciences</td>
</tr>
<tr>
<td >
				CUSIP:</td>
<td _msthash="6545084" _msttexthash="70031" >
				89854F 106</td>
</tr>
<tr>
<td >
				Isin:</td>
<td _msthash="6546410" _msttexthash="108186" >
				CA89854F 1062</td>
</tr>
<tr>
<td >
				Boardlot/Quotity:</td>
<td _msthash="6547736" _msttexthash="15431" >
				500</td>
</tr>
<tr>
<td >
				IPO Price/Price:</td>
<td _msthash="6606678" _msttexthash="79144" >
				$0.25/0.25$</td>
</tr>
<tr>
<td >
				Agent:</td>
<td _msthash="6608017" _msttexthash="460447" >
<div >
<div >
						Canaccord Genuity&nbsp;Corp.</div>
</div>
</td>
</tr>
<tr>
<td >
				Trading Currency/Currency Trading:</td>
<td _msthash="6609356" _msttexthash="78221" >
				$CDN/CDN$</td>
</tr>
<tr>
<td >
				Listing Date/Date of registration:</td>
<td _msthash="6610695" _msttexthash="524069" >
				December 16&nbsp;2020/decembre 16&nbsp;2020</td>
</tr>
<tr>
<td >
				Trading Date/Negotiation Date:</td>
<td _msthash="6612034" _msttexthash="522951" >
				December 18&nbsp;2020/decembre 18&nbsp;2020</td>
</tr>
<tr>
<td >
				Other Exchanges/Other Marches:</td>
<td _msthash="6613373" _msttexthash="19591" >
				N/A</td>
</tr>
<tr>
<td >
				Fiscal Year end / Closing of the fiscal year:</td>
<td _msthash="6614712" _msttexthash="106483" >
				August 31/aout 31</td>
</tr>
<tr>
<td >
				Transfer Agent/Transfer Agent:</td>
<td _msthash="6616051" _msttexthash="1001507" >
				Computershare Investor Services Inc.</td>
</tr>
</tbody>
</table>

	The Exchange is accepting Market Maker applications for TRYP. Please email:&nbsp;<a href="mailto:Trading@theCSE.com" >Trading@theCSE.com</a>

	If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail:&nbsp;<a href="mailto:Listings@thecse.com" >Listings@thecse.com</a>

	For further information, please contact the registration department at 416-367-7340 or&nbsp;<a _istranslated="1" href="mailto:Listings@thecse.com" >email: Listings@thecse.com</a>

Tryp Therapeutics Inc.

2020-1225 - New Listing - Tryp Therapeutics Inc (TRYP)

CSE25™

CSE Composite Index®

In this series, we delve deep into the experiences of CSE listed companies, exploring their past successes and future opportunities.

CSE Issuer Spotlight

**Follow us** for the **latest news** from the CSE

 The CSE provides a modern and efficient alternative for companies looking to access the Canadian public capital markets.

The Canadian Securities Exchange (CSE)

Learn how we streamline issuer regulation through enhanced disclosure, practical and effective regulatory oversight, and modern technology.

Listing on the CSE

Learn more about the companies we list and how to get started trading on the CSE.

Investing in Listed Companies

Learn how we lower costs, reduce complexity, and provide market making opportunities for the dealer community.

Trading on the CSE

Whether you’re an investor, business leader, or simply looking to learn more, start your journey with the CSE here.

Get Started

From announcements and market updates to in-depth interviews with company leaders - stay informed with the latest from the CSE.

Latest from the CSE

Discover newly listed companies on the CSE through our series of bite-sized interviews with company leaders.

Get to know our latest listings

Listed Company News

Market Activity

List with the CSE

Find a home for your next big idea.

Frequently Asked Questions

How does being listed on the CSE affect me as a shareholder?

Where do I get information and trade CSE listed securities?

Where can I find an RSS feed for listed company news?

Where is the CSE recognized?

Upcoming Events

join the list

Join our mailing list to receive buy-in notifications

The CSE provides a superior exchange experience by investing in our customers’ success with innovation, dedication, and passion.

Where innovation, passion, and trust intersect

We strive to be the most innovative exchange in Canada. We aim to offer unlimited global access and a customized client-centric experience while delivering the lowest cost of public capital. 

We are Canada's entrepreneurial exchange

The most searched CSE listed companies on thecse.com

Recent Quotes

Get the latest regulatory announcements from the CSE concerning its Listings Policies, Trading Rules and functionality and other important industry developments.

Notices

Get the latest information about new CSE listings, the appointment of Market Makers, market events, and other news.

Bulletins

Stay informed with CSE listed company news, providing transparency and accountability to shareholders and the public.

Company News

Stay Informed

The **total volume** traded on the CSE today is

Connect with our professionals and listing experts at industry events and conferences.